CD274 and neoplasm: The co-delivery of doxorubicin with PD-L1 siRNA, which can inhibit PD-L1 expression and reactivate immune responses against malignant cells, using peptide-modified carboxymethyl chitosan micelles enhanced the anti-tumor effect in an orthotopic-tumor-bearing mouse model when administered i.v. [245].